Dashboard
Manage Tickers

AXSM Axsome Therapeutics, Inc.

Nasdaq axsome.com


$ 128.99 $ 0.00 (0 %)    

Monday, 03-Nov-2025 08:25:46 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.21 $ 0.00 (0 %)
DIA $ 475.44 $ 0.00 (0 %)
SPY $ 684.07 $ 0.00 (0 %)
TLT $ 89.65 $ 0.00 (0 %)
GLD $ 369.49 $ 0.00 (0 %)
$ 134.99
$ 132.21
$ 127.38 x 8
$ 129.00 x 9
-- - --
$ 75.56 - $ 139.13
508,233
na
6.74B
$ 0.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-04-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 02-18-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-23-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-02-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-15-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-07-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-07-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-11-2016 03-31-2016 10-Q
39 03-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

axsome-therapeutics-q3-adj-eps-068-beats-087-estimate
Axsome Therapeutics Q3 Adj. EPS $(0.68) Be...
11/03/2025 12:11:47

axsome-therapeutics-q3-sales-170992m-beat-162545m-estimate
Axsome Therapeutics Q3 Sales $170.992M Bea...
11/03/2025 12:01:12

earnings-scheduled-for-november-3-2025
Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

uncovering-potential-axsome-therapeuticss-earnings-preview
Uncovering Potential: Axsome Therapeutics'...
10/31/2025 18:01:47

morgan-stanley-maintains-overweight-on-axsome-therapeutics-raises-price-target-to-194
Morgan Stanley Maintains Overweight on Axs...
10/20/2025 15:24:09

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target...

b-riley-securities-initiates-coverage-on-axsome-therapeutics-with-buy-rating-announces-price-target-of-179
B. Riley Securities Initiates Coverage On ...
10/01/2025 14:33:10

B. Riley Securities analyst Madison El-Saadi initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and a...

a-glimpse-into-the-expert-outlook-on-axsome-therapeutics-through-8-analysts
A Glimpse Into The Expert Outlook On Axsom...
09/03/2025 14:00:32

wells-fargo-assumes-axsome-therapeutics-at-overweight-announces-price-target-of-163
Wells Fargo Assumes Axsome Therapeutics at...
09/03/2025 12:51:46

Wells Fargo analyst Benjamin Burnett assumes Axsome Therapeutics (NASDAQ:AXSM) with a Overweight rating and announces Price ...

tonix-pharmas-drug-gets-fda-nod-for-chronic-pain-condition-first-new-therapy-in-over-15-years
Tonix Pharma's Drug Gets FDA Nod For Chron...
08/18/2025 13:45:18

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.

axsome-therapeutics-analysts-increase-their-forecasts-after-q2-earnings
Axsome Therapeutics Analysts Increase Thei...
08/05/2025 17:40:51

b-of-a-securities-maintains-buy-on-axsome-therapeutics-raises-price-target-to-176
B of A Securities Maintains Buy on Axsome ...
08/05/2025 14:13:02

B of A Securities analyst Jason Gerberry maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target ...

rbc-capital-maintains-outperform-on-axsome-therapeutics-raises-price-target-to-189
RBC Capital Maintains Outperform on Axsome...
08/05/2025 13:08:43

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price targe...

where-axsome-therapeutics-stands-with-analysts
Where Axsome Therapeutics Stands With Anal...
08/04/2025 13:02:15

needham-reiterates-buy-on-axsome-therapeutics-maintains-150-price-target
Needham Reiterates Buy on Axsome Therapeut...
08/04/2025 12:02:42

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $150 price target.

axsome-therapeutics-q2-adj-eps-047-beats-107-estimate-sales-15004m-beat-14033m-estimate
Axsome Therapeutics Q2 Adj. EPS $(0.47) Be...
08/04/2025 11:02:02

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For August 4, 2025
08/04/2025 08:32:29

a-look-at-axsome-therapeuticss-upcoming-earnings-report
A Look at Axsome Therapeutics's Upcoming E...
08/01/2025 17:04:18

axsome-therapeutics-spotlights-broad-clinical-pipeline-in-alzheimers-agitation-mdd-narcolepsy-and-fibromyalgia-at-new-york-investor-event
Axsome Therapeutics Spotlights Broad Clini...
07/21/2025 11:37:50

Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD,...

where-axsome-therapeutics-stands-with-analysts
Where Axsome Therapeutics Stands With Anal...
07/03/2025 19:01:43

morgan-stanley-assumes-axsome-therapeutics-at-overweight-announces-price-target-of-190
Morgan Stanley Assumes Axsome Therapeutics...
07/03/2025 17:44:57

Morgan Stanley analyst Sean Laaman assumes Axsome Therapeutics (NASDAQ:AXSM) with a Overweight rating and announces Price Ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION